Gustave Roussy Canc Campus

• 2023 Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib.

Download
 RDF/XML-Format
 JSON-LD-Format
 Turtle-Format
 N3-Format